2 weeks Ago By ABMN Staff
JPMorgan Chase & Co. lessened its position in PROCEPT BioRobotics Co. ( NASDAQ:PRCT – Free Report ) by 24.
3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 615,166 shares of the company’s stock after selling 197,200 shares during the quarter. JPMorgan Chase & Co.
’s holdings in PROCEPT BioRobotics were worth $49,533,000 as of its most recent filing with the Securities & Exchange Commission. Several other hedge funds also recently made changes to their positions in PRCT. Perpetual Ltd purchased a new stake in PROCEPT BioRobotics in the fourth quarter worth about $66,972,000.
Franklin Resources Inc. raised its stake in PROCEPT BioRobotics by 64.5% during the third quarter.
Franklin Resources Inc. now owns 885,992 shares of the company’s stock valued at $64,669,000 after buying an additional 347,330 shares during the last quarter. Vanguard Group Inc.
boosted its holdings in PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc.
now owns 5,140,426 shares of the company’s stock worth $413,907,000 after acquiring an additional 297,075 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of PROCEPT BioRobotics by 218.1% in the fourth quarter.
Allspring Global Investments Holdings LLC now owns 401,210 shares of the company’s stock worth $33,350,000 after acquiring an additional 275,071 shares during the last quarter. Finally, Lord Abbett & CO. LLC increased its holdings in shares of PROCEPT BioRobotics by 45.
3% during the third quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company’s stock valued at $59,974,000 after acquiring an additional 233,430 shares in the last quarter.
89.46% of the stock is currently owned by institutional investors. Analyst Upgrades and Downgrades A number of equities analysts recently issued reports on PRCT shares.
Truist Financial reiterated a “buy” rating and issued a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th.
Morgan Stanley cut their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th.
One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.
29. Insider Buying and Selling at PROCEPT BioRobotics In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.
06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company’s stock, valued at approximately $6,161,966.
46. The trade was a 0.67 % decrease in their ownership of the stock.
The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website . Also, CEO Reza Zadno sold 5,475 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.
06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at $9,875,374.
20. This trade represents a 3.07 % decrease in their position.
The disclosure for this sale can be found here . Insiders sold a total of 6,455 shares of company stock worth $368,322 in the last three months. 17.
40% of the stock is currently owned by company insiders. PROCEPT BioRobotics Stock Down 6.5 % Shares of PROCEPT BioRobotics stock opened at $51.
23 on Friday. PROCEPT BioRobotics Co. has a twelve month low of $46.
99 and a twelve month high of $103.81. The company has a quick ratio of 5.
07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.
The company’s 50 day moving average is $63.77 and its 200 day moving average is $76.98.
The company has a market cap of $2.81 billion, a price-to-earnings ratio of -26.27 and a beta of 1.
09. PROCEPT BioRobotics ( NASDAQ:PRCT – Get Free Report ) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.
35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01).
The firm had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million.
PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%.
Research analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.
PROCEPT BioRobotics Company Profile ( Free Report ) PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). Read More Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. ( NASDAQ:PRCT – Free Report ). Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.
com's FREE daily email newsletter ..
